THOMAS WHEELER to Genetic Therapy
This is a "connection" page, showing publications THOMAS WHEELER has written about Genetic Therapy.
Connection Strength
0.469
-
GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res. 2011 Nov 15; 17(22):7174-82.
Score: 0.064
-
Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther. 2006 Apr; 13(4):716-28.
Score: 0.044
-
Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancer. Technol Cancer Res Treat. 2006 Feb; 5(1):23-36.
Score: 0.044
-
Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients. Int J Radiat Oncol Biol Phys. 2004 Jun 01; 59(2):562-71.
Score: 0.039
-
Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1520-9.
Score: 0.038
-
Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer. Oncologist. 2002; 7(5):458-66.
Score: 0.033
-
Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report. Int J Radiat Oncol Biol Phys. 2001 Nov 01; 51(3):605-13.
Score: 0.032
-
Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther. 2001 Nov 01; 12(16):1955-67.
Score: 0.032
-
In situ gene therapy for prostate cancer: immunomodulatory approaches. Expert Opin Biol Ther. 2001 May; 1(3):481-95.
Score: 0.031
-
In vivo adenovirus-mediated suicide gene therapy of orthotopic bladder cancer. Mol Ther. 2000 Sep; 2(3):211-7.
Score: 0.030
-
Cytopathic effect of in situ gene therapy in prostate cancer. Hum Pathol. 2000 Jul; 31(7):866-70.
Score: 0.030
-
In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther. 1999 May 01; 10(7):1239-49.
Score: 0.027
-
Adenovirus-mediated suicide gene therapy for experimental bladder cancer. Urology. 1997 Feb; 49(2):173-80.
Score: 0.023